{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:13:30Z","timestamp":1785150810443,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05294-w","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:54:27Z","timestamp":1776228867000},"page":"14421-14437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u03b2-defensin-3 promoted osteosarcoma progression via activating the PI3K\/AKT pathway and regulated tumor immune response"],"prefix":"10.1007","volume":"399","author":[{"given":"Kang","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"5294_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume":"1248","author":"L Ai","year":"2020","unstructured":"Ai L, Xu A, Xu J (2020) Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol 1248:33\u201359","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"5294_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/sj.leu.2402824","volume":"17","author":"F Chang","year":"2003","unstructured":"Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL et al (2003) Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17(3):590\u2013603","journal-title":"Leukemia"},{"key":"5294_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.molimm.2024.02.013","volume":"168","author":"G Chen","year":"2024","unstructured":"Chen G, Zheng Y, Wu N, Yang X, Qu S (2024) Human beta defensin 3 knockdown inhibits the proliferation and migration of airway smooth muscle cells through regulating the PI3K\/AKT signaling pathway. Mol Immunol 168:38\u201346","journal-title":"Mol Immunol"},{"issue":"8","key":"5294_CR4","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1080\/10428194.2021.1885667","volume":"62","author":"S Desai","year":"2021","unstructured":"Desai S, Ansell SM (2021) Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond. Leuk Lymphoma 62(8):1795\u20131804","journal-title":"Leuk Lymphoma"},{"key":"5294_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101582","volume":"27","author":"Y Du","year":"2023","unstructured":"Du Y, Yang Y, Zhang W, Yang C, Xu P (2023) Human \u03b2-defensin-3 and nuclear factor-kappa B p65 synergistically promote the cell proliferation and invasion of oral squamous cell carcinoma. Transl Oncol 27","journal-title":"Transl Oncol"},{"issue":"Suppl 2","key":"5294_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28352","volume":"68","author":"BR Eaton","year":"2021","unstructured":"Eaton BR, Schwarz R, Vatner R, Yeh B, Claude L, Indelicato DJ et al (2021) Osteosarcoma Pediatric Blood & Cancer 68(Suppl 2)","journal-title":"Osteosarcoma Pediatric Blood & Cancer"},{"issue":"2","key":"5294_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/jid.2012.319","volume":"133","author":"LK Ferris","year":"2013","unstructured":"Ferris LK, Mburu YK, Mathers AR, Fluharty ER, Larregina AT, Ferris RL et al (2013) Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant. J Invest Dermatol 133(2):460\u20138","journal-title":"J Invest Dermatol"},{"issue":"2","key":"5294_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonz\u00e1lez-Bar\u00f3n M (2004) PI3K\/Akt signalling pathway and cancer. Cancer Treat Rev 30(2):193\u2013204","journal-title":"Cancer Treat Rev"},{"issue":"47","key":"5294_CR9","doi-asserted-by":"publisher","first-page":"18631","DOI":"10.1073\/pnas.0702130104","volume":"104","author":"N Funderburg","year":"2007","unstructured":"Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV et al (2007) Human \u03b2-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci U S A 104(47):18631\u201318635","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5294_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00341","volume":"9","author":"SK Ghosh","year":"2019","unstructured":"Ghosh SK, McCormick TS, Weinberg A (2019) Human beta defensins and cancer: contradictions and common ground. Front Oncol 9","journal-title":"Front Oncol"},{"key":"5294_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8040161","author":"MP Gomez Hernandez","year":"2019","unstructured":"Gomez Hernandez MP, Bates AM, Starman EE, Lanzel EA, Comnick C, Xie XJ et al (2019) HBD3 induces PD-L1 expression on head and neck squamous cell carcinoma cell lines. Antibiotics (Basel, Switzerland). https:\/\/doi.org\/10.3390\/antibiotics8040161","journal-title":"Antibiotics (Basel, Switzerland)"},{"issue":"11","key":"5294_CR12","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.21873\/anticanres.11188","volume":"36","author":"Y Hanaoka","year":"2016","unstructured":"Hanaoka Y, Yamaguchi Y, Yamamoto H, Ishii M, Nagase T, Kurihara H et al (2016) In vitro and in vivo anticancer activity of human \u03b2-defensin-3 and its mouse homolog. Anticancer Res 36(11):5999\u20136004","journal-title":"Anticancer Res"},{"issue":"4","key":"5294_CR13","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2025.2826","volume":"22","author":"K Hashimoto","year":"2025","unstructured":"Hashimoto K, Nishimura S, Goto K (2025) PD\u20111\/PD\u2011L1 immune checkpoint in bone and soft tissue tumors (review). Mol Clin Oncol 22(4)","journal-title":"Mol Clin Oncol"},{"issue":"27","key":"5294_CR14","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","volume":"33","author":"MS Isakoff","year":"2015","unstructured":"Isakoff MS, Bielack SS, Meltzer P, Gorlick R (2015) Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 33(27):3029\u20133035","journal-title":"J Clin Oncol"},{"issue":"5","key":"5294_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y (2019) PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother 15(5):1111\u20131122","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"5294_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cellimm.2015.06.004","volume":"297","author":"CJ Judge","year":"2015","unstructured":"Judge CJ, Reyes-Aviles E, Conry SJ, Sieg SS, Feng Z, Weinberg A et al (2015) HBD-3 induces NK cell activation, IFN-\u03b3 secretion and mDC dependent cytolytic function. Cell Immunol 297(2):61\u20138","journal-title":"Cell Immunol"},{"key":"5294_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jbiotec.2025.11.018","volume":"410","author":"Y Kamaraj","year":"2026","unstructured":"Kamaraj Y, Kumaresan V, Hu J, Zhu D (2026) Human beta-defensin 3-functionalized Fe\/GMP nanozyme for multifunctional antimicrobial and anticancer activity against Helicobacter pylori-associated gastrointestinal cancer. J Biotechnol 410:67\u201383","journal-title":"J Biotechnol"},{"issue":"8","key":"5294_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.oraloncology.2008.10.016","volume":"45","author":"HI Kawsar","year":"2009","unstructured":"Kawsar HI, Weinberg A, Hirsch SA, Venizelos A, Howell S, Jiang B et al (2009) Overexpression of human beta-defensin-3 in oral dysplasia: potential role in macrophage trafficking. Oral Oncol 45(8):696\u2013702","journal-title":"Oral Oncol"},{"issue":"50","key":"5294_CR19","doi-asserted-by":"publisher","first-page":"7443","DOI":"10.1038\/sj.onc.1209091","volume":"24","author":"L Larue","year":"2005","unstructured":"Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3\u2019 kinase\/AKT pathways. Oncogene 24(50):7443\u201354","journal-title":"Oncogene"},{"issue":"5","key":"5294_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/2326-6066.CIR-22-0317","volume":"11","author":"L Li","year":"2023","unstructured":"Li L, Hao S, Gao M, Liu J, Xu X, Huang J et al (2023) HDAC3 inhibition promotes antitumor immunity by enhancing CXCL10-mediated chemotaxis and recruiting of immune cells. Cancer Immunol Res 11(5):657\u201373","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"5294_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z et al (2020) PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 11(9)","journal-title":"Cell Death Dis"},{"issue":"2","key":"5294_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/carcin\/bgq236","volume":"32","author":"YK Mburu","year":"2011","unstructured":"Mburu YK, Abe K, Ferris LK, Sarkar SN, Ferris RL (2011) Human \u03b2-defensin 3 promotes NF-\u03baB-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck. Carcinogenesis 32(2):168\u2013174","journal-title":"Carcinogenesis"},{"issue":"3","key":"5294_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1189\/jlb.0612300","volume":"94","author":"JP Meisch","year":"2013","unstructured":"Meisch JP, Vogel RM, Schlatzer DM, Li X, Chance MR, Levine AD (2013) Human \u03b2-defensin 3 induces STAT1 phosphorylation, tyrosine phosphatase activity, and cytokine synthesis in T cells. J Leukoc Biol 94(3):459\u2013471","journal-title":"J Leukoc Biol"},{"issue":"1","key":"5294_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12070-024-05129-1","volume":"77","author":"V Mohan","year":"2025","unstructured":"Mohan V, Patro SK, Purohit P, Sharma V, Soni K, Choudhury B et al (2025) Pioneering clinical investigation: beta defensin expression in patients of squamous cell carcinoma of oral cavity as a forward-looking validation for molecular treatment. Indian J Otolaryngol Head Neck Surg 77(1):149\u201354","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"5294_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","volume":"48","author":"JS O'Donnell","year":"2018","unstructured":"O\u2019Donnell JS, Massi D, Teng MWL, Mandala M (2018) PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol 48:91\u2013103","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"5294_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1023\/B:APPT.0000045801.15585.dd","volume":"9","author":"M Osaki","year":"2004","unstructured":"Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9(6):667\u2013676","journal-title":"Apoptosis"},{"issue":"2","key":"5294_CR27","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.18632\/oncotarget.6520","volume":"7","author":"TK Phan","year":"2016","unstructured":"Phan TK, Lay FT, Poon IK, Hinds MG, Kvansakul M, Hulett MD (2016) Human \u03b2-defensin 3 contains an oncolytic motif that binds PI(4,5)P2 to mediate tumour cell permeabilisation. Oncotarget 7(2):2054\u20132069","journal-title":"Oncotarget"},{"issue":"1","key":"5294_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/imcb.1017","volume":"96","author":"TK Phan","year":"2018","unstructured":"Phan TK, Lay FT, Hulett MD (2018) Importance of phosphoinositide binding by human \u03b2-defensin 3 for Akt-dependent cytokine induction. Immunol Cell Biol 96(1):54\u201367","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"5294_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2174\/1566523215666150126123642","volume":"15","author":"D Rafael","year":"2015","unstructured":"Rafael D, Doktorovov\u00e1 S, Florindo HF, Gener P, Abasolo I, Schwartz S Jr et al (2015) EMT blockage strategies: targeting Akt dependent mechanisms for breast cancer metastatic behaviour modulation. Curr Gene Ther 15(3):300\u2013312","journal-title":"Curr Gene Ther"},{"issue":"30","key":"5294_CR30","doi-asserted-by":"publisher","first-page":"28988","DOI":"10.18632\/oncotarget.4902","volume":"6","author":"V Salvatore","year":"2015","unstructured":"Salvatore V, Focaroli S, Teti G, Mazzotti A, Falconi M (2015) Changes in the gene expression of co-cultured human fibroblast cells and osteosarcoma cells: the role of microenvironment. Oncotarget 6(30):28988\u201328998","journal-title":"Oncotarget"},{"issue":"7","key":"5294_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/2326-6066.CIR-13-0224","volume":"2","author":"JK Shen","year":"2014","unstructured":"Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J et al (2014) Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2(7):690\u2013698","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"5294_CR32","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W et al (2019) Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol 6(1):e12\u2013e19","journal-title":"Lancet Haematol"},{"issue":"4","key":"5294_CR33","first-page":"328","volume":"26","author":"VM Shnitsar","year":"2004","unstructured":"Shnitsar VM, Lisovskiy IL, Soldatkina MA, Nespryadko SV, Turchak OV, Vinnitskaya AB et al (2004) Human beta-defensin 3 (hBD-3) expression in A431 cell line and human vulval tumors. Exp Oncol 26(4):328\u2013330","journal-title":"Exp Oncol"},{"issue":"12","key":"5294_CR34","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","volume":"18","author":"NL Syn","year":"2017","unstructured":"Syn NL, Teng MWL, Mok TSK, Soo RA (2017) De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 18(12):e731\u2013e741","journal-title":"Lancet Oncol"},{"issue":"8","key":"5294_CR35","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/14712598.2020.1762561","volume":"20","author":"B Tang","year":"2020","unstructured":"Tang B, Chi Z, Guo J (2020) Toripalimab for the treatment of melanoma. Expert Opin Biol Ther 20(8):863\u2013869","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"5294_CR36","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3892\/ijo.2014.2507","volume":"45","author":"S Uraki","year":"2014","unstructured":"Uraki S, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Ogura S et al (2014) Human \u03b2-defensin-3 inhibits migration of colon cancer cells via downregulation of metastasis-associated 1 family, member 2 expression. Int J Oncol 45(3):1059\u20131064","journal-title":"Int J Oncol"},{"issue":"5","key":"5294_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z et al (2021) Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol 7(5):709\u2013717","journal-title":"JAMA Oncol"},{"issue":"46","key":"5294_CR38","doi-asserted-by":"publisher","first-page":"75902","DOI":"10.18632\/oncotarget.12426","volume":"7","author":"D Xu","year":"2016","unstructured":"Xu D, Zhang B, Liao C, Zhang W, Wang W, Chang Y et al (2016) Human beta-defensin 3 contributes to the carcinogenesis of cervical cancer via activation of NF-\u03baB signaling. Oncotarget 7(46):75902\u201375913","journal-title":"Oncotarget"},{"issue":"4","key":"5294_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.path.2021.06.003","volume":"14","author":"A Yoshida","year":"2021","unstructured":"Yoshida A (2021) Osteosarcoma: old and new challenges. Surg Pathol Clin 14(4):567\u2013583","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"5294_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X (2024) Advances on immunotherapy for osteosarcoma. Mol Cancer 23(1)","journal-title":"Mol Cancer"},{"issue":"1","key":"5294_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00363-7","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang L, Lin W, Tan F, Li N, Xue Q, Gao S et al (2022) Sintilimab for the treatment of non-small cell lung cancer. Biomark Res 10(1)","journal-title":"Biomark Res"},{"key":"5294_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2025.214576","volume":"180","author":"R Zhang","year":"2026","unstructured":"Zhang R, Yin X, Xu Z, Yan Q (2026) Novel Ce\/Cu-modified black ceramics disrupted mitochondrial dysfunction and tricarboxylic acid cycle to induce cuproptosis in osteosarcoma cells. Biomater Adv 180","journal-title":"Biomater Adv"},{"issue":"4","key":"5294_CR43","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3892\/etm.2016.3579","volume":"12","author":"C Zhu","year":"2016","unstructured":"Zhu C, Bao NR, Chen S, Zhao JN (2016) HBD-3 regulation of the immune response and the LPS\/TLR4-mediated signaling pathway. Exp Ther Med 12(4):2150\u20132154","journal-title":"Exp Ther Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05294-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05294-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05294-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:43:35Z","timestamp":1783914215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05294-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5294"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05294-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Ethics Committee of Yantaishan Hospital (Ethics No.\u00a02025-L040) and complied with the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}